基石藥業-B(02616.HK):精準治療藥物阿伐替尼片(泰吉華®)獲中國首部《成人系統性肥大細胞增多症診斷與治療中國指南》納入用藥推薦
格隆匯2月14日丨基石藥業-B(02616.HK)發佈公吿,日前發佈的中國首部系統性肥大細胞增多症(“SM”)臨牀診療指南 —《成人系統性肥大細胞增多症診斷與治療中國指南》(“指南”)將阿伐替尼片(泰吉華®)納入用藥推薦,用於治療晚期SM。阿伐替尼片(泰吉華)是一款強效、高選擇性、口服針對KIT和PDGFRA突變的激酶抑制劑,基石藥業與Blueprint Medicines Corporation (NASDAQ: BPMC) 達成獨家合作和授權協議,獲得了阿伐替尼片在中國大陸、中國香港、中國澳門和中國台灣地區的獨家開發和商業化權利。
基石藥業大中華區總經理兼商業部負責人周遊博士表示:“晚期SM是一種罕見的血液系統疾病,幾乎所有患者均由KITD816V突變驅動。阿伐替尼片(泰吉華)作為KIT D816V突變點位的強效高選擇性抑制劑,可靶嚮導致肥大細胞失控性增殖和激活的疾病驅動基因。此次阿伐替尼片(泰吉華)被納入指南作為用藥推薦是基因驅動精準治療改變臨牀實踐的有力體現。一直以來,基石藥業始終致力於研發同類首創或同類最優藥物,滿足患者未解決的醫療需求。基石藥業將繼續全面提升藥品的可及性和可支付性,力爭讓更多的患者用得上、用得起全球領先的好藥。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.